Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | TGM2 | P21980 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12251784 | 0.86 | MAPT (0.59) | HTTSMN1; SMN2MAPTL3MBTL1TGM2 | |
| SCHEMBL968445 | 0.85 | HTT (0.63) | HTTSMN1; SMN2MAPTL3MBTL1TGM2 | |
| SCHEMBL16804706 | 0.85 | HTT (0.62) | HTTSMN1; SMN2MAPTL3MBTL1TGM2 | |
| SCHEMBL16804701 | 0.85 | HTT (0.62) | HTTSMN1; SMN2MAPTL3MBTL1TGM2 | |
| SCHEMBL917677 | 0.84 | HTT (0.65) | HTTSMN1; SMN2TGM2LMNAKEAP1 | |
| SCHEMBL6748819 | 0.84 | HTT (0.72) | HTTSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL16804702 | 0.84 | HTT (0.60) | HTTSMN1; SMN2MAPTL3MBTL1TGM2 | |
| SCHEMBL16572084 | 0.83 | L3MBTL1 (0.69) | HTTSMN1; SMN2NPC1RAB9AMAPT | |
| SCHEMBL30605297 | 0.83 | HTT (0.63) | HTTSMN1; SMN2TGM2LMNAKEAP1 | |
| SCHEMBL916687 | 0.83 | HTT (0.60) | HTTSMN1; SMN2MAPTL3MBTL1TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786426-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | Parion Sciences, Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006022935-A1 | SOLUBLE AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20050090505-A1 | Methods of reducing risk of infection from pathogens | JOHNSON MICHAEL R (US) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090505-A1 | Methods of reducing risk of infection from pathogens | KCNN3, KCNN1, KCNN2 | HTT 2397/4885SMN1; SMN2 1966/4885NPC1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.